Imeik Technology Development Co (300896) Q3 2025 earnings summary

Executive summary

• Revenue for the first nine months of 2025 was ¥1.86 billion, down 21.49% year-over-year.

• Net profit attributable to shareholders was ¥1.09 billion, a decrease of 31.05% year-over-year.

• The company completed the acquisition of REGEN Biotech, Inc., significantly increasing goodwill and minority interests.

Financial highlights

• Q3 revenue was ¥565.78 million, down 21.27% compared to the same quarter last year.

• Q3 net profit attributable to shareholders was ¥303.80 million, down 34.61% year-over-year.

• Basic and diluted EPS for the first nine months were ¥3.63, down 30.99% year-over-year.

• Operating cash flow for the first nine months was ¥1.07 billion, down 30.12% year-over-year.

• Gross margin and other profitability metrics declined due to lower revenue and increased costs.

Outlook and guidance

• Management attributes declines to lower sales and increased expenses, with no explicit forward guidance provided.